William Blair Has Negative Outlook for Enovis Q4 Earnings

Enovis Co. (NYSE:ENOV - Free Report) - Stock analysts at William Blair cut their Q4 2024 earnings per share estimates for Enovis in a research report issued to clients and investors on Wednesday, November 6th. William Blair analyst B. Vazquez now anticipates that the company will earn $0.91 per share for the quarter, down from their previous estimate of $0.95. The consensus estimate for Enovis' current full-year earnings is $2.79 per share. William Blair also issued estimates for Enovis' Q4 2025 earnings at $0.96 EPS.

A number of other equities research analysts have also weighed in on ENOV. JMP Securities initiated coverage on shares of Enovis in a research note on Thursday, October 3rd. They set an "outperform" rating and a $62.00 target price for the company. Evercore ISI reduced their price target on Enovis from $62.00 to $58.00 and set an "outperform" rating on the stock in a report on Tuesday, October 1st. Needham & Company LLC reaffirmed a "buy" rating and issued a $65.00 price objective on shares of Enovis in a research note on Thursday. Finally, JPMorgan Chase & Co. lowered their target price on shares of Enovis from $53.00 to $50.00 and set a "neutral" rating for the company in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $67.00.

Enovis Trading Up 2.0 %

Enovis stock traded up $0.94 during mid-day trading on Monday, reaching $47.36. 526,741 shares of the company traded hands, compared to its average volume of 584,054. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.08. The firm has a market capitalization of $2.65 billion, a price-to-earnings ratio of -21.63 and a beta of 1.91. The firm's 50 day moving average price is $42.24 and its 200 day moving average price is $45.38. Enovis has a 52-week low of $38.27 and a 52-week high of $65.03.

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.11. The business had revenue of $505.22 million during the quarter, compared to analyst estimates of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. During the same quarter in the previous year, the firm earned $0.56 EPS. The company's quarterly revenue was up 21.0% compared to the same quarter last year.

Hedge Funds Weigh In On Enovis

A number of hedge funds have recently bought and sold shares of ENOV. Ridgewood Investments LLC acquired a new stake in shares of Enovis during the 2nd quarter valued at $44,000. DekaBank Deutsche Girozentrale acquired a new stake in Enovis in the 3rd quarter valued at $55,000. Innealta Capital LLC bought a new position in shares of Enovis in the second quarter valued at approximately $65,000. Benjamin F. Edwards & Company Inc. raised its holdings in shares of Enovis by 28.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company's stock valued at $76,000 after buying an additional 371 shares during the last quarter. Finally, Heritage Family Offices LLP acquired a new position in Enovis during the 3rd quarter worth $206,000. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.